Kyu HH, Stein CE, Boschi Pinto C et al (2018) Causes of death among children aged 5–14 years in the WHO European Region: a systematic analysis for the global burden of Disease Study 2016. Lancet Child Adolesc Heal 2:321–337. https://doi.org/10.1016/S2352-4642(18)30095-6

Article  Google Scholar 

Janssen JM, Dorlo TPC, Steeghs N et al (2020) Pharmacokinetic targets for therapeutic drug monitoring of small molecule kinase inhibitors in Pediatric Oncology. Clin Pharmacol Ther 108:494–505. https://doi.org/10.1002/cpt.1808

Article  PubMed  Google Scholar 

Kaczmarska A, Śliwa P, Lejman M, Zawitkowska J (2021) The use of inhibitors of tyrosine kinase in Paediatric Haemato-Oncology-when and why? Int J Mol Sci 22. https://doi.org/10.3390/ijms222112089

Verschuur AC, Bajčiová V, Mascarenhas L et al (2019) Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. Cancer Chemother Pharmacol 84:41–50. https://doi.org/10.1007/s00280-019-03814-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

EMA (2018) Reflection paper on the use of extrapolation in the development of medicines for paediatrics

EMA/CHMP (2022) Structured guidance on the use of extrapolation

Burckart G, Pediatric Extrapolation (2023) Jul in FDA Submissions – Sources of Data. https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-extrapolation-fda-submissions-sources-data-g-burckart_en.pdf. Accessed 30

Mulugeta L, Experience in FDA Submissions with Matching Pediatric Drug Exposure to Adult Drug Exposure. https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cersievents/pediatricpbpk/Mulugeta-exposure matching in FDA submissions_final2.pdf. Accessed 30 Jul 2023

Champagne MA, Capdeville R, Krailo M et al (2004) Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children’s Oncology Group phase 1 study. Blood 104:2655–2660. https://doi.org/10.1182/blood-2003-09-3032

Article  CAS  PubMed  Google Scholar 

Zwaan CM, Rizzari C, Mechinaud F et al (2013) Dasatinib in Children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with Cancer Consortium. J Clin Oncol 31:2460–2468. https://doi.org/10.1200/JCO.2012.46.8280

Article  CAS  PubMed  Google Scholar 

Hijiya N, Zwaan CM, Rizzari C et al (2020) Pharmacokinetics of Nilotinib in Pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or Acute Lymphoblastic Leukemia. Clin Cancer Res 26:812–820. https://doi.org/10.1158/1078-0432.CCR-19-0090

Article  CAS  PubMed  Google Scholar 

Widemann BC, Kim A, Fox E et al (2012) A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a children’s Oncology Group Phase I Consortium report. Clin cancer Res off J Am Assoc Cancer Res 18:6011–6022. https://doi.org/10.1158/1078-0432.CCR-11-3284

Article  CAS  Google Scholar 

Meneses-Lorente G, Guerini E, Mercier F et al (2023) Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations. Cancer Chemother Pharmacol 91:239–246. https://doi.org/10.1007/s00280-023-04510-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balis FM, Thompson PA, Mosse YP et al (2017) First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium. Cancer Chemother Pharmacol 79:181–187. https://doi.org/10.1007/s00280-016-3220-6

Article  CAS  PubMed  Google Scholar 

Mossé YP, Lim MS, Voss SD et al (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 14:472–480. https://doi.org/10.1016/S1470-2045(13)70095-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Cock RFW, Piana C, Krekels EHJ et al (2011) The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67 Suppl 1:5–16. https://doi.org/10.1007/s00228-009-0782-9

Article  Google Scholar 

Wang K, Jiang K, Wei X et al (2021) Physiologically based pharmacokinetic models are effective support for Pediatric Drug Development. AAPS PharmSciTech 22:208. https://doi.org/10.1208/s12249-021-02076-w

Article  PubMed  Google Scholar 

Calvier EAM, Krekels EHJ, Välitalo PAJ et al (2017) Allometric scaling of Clearance in Paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet 56:273–285. https://doi.org/10.1007/s40262-016-0436-x

Article  PubMed  Google Scholar 

Mould DR, Upton RN (2013) Basic concepts in Population modeling, Simulation, and model-based Drug Development—Part 2: introduction to Pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2:38. https://doi.org/10.1038/psp.2013.14

Article  CAS  Google Scholar 

Jones HM, Rowland-Yeo K (2013) Basic concepts in physiologically based pharmacokinetic modeling in Drug Discovery and Development. CPT Pharmacometrics Syst Pharmacol 2:63. https://doi.org/10.1038/psp.2013.41

Article  CAS  Google Scholar 

Mahmood I, Tegenge MA (2019) A comparative study between Allometric Scaling and physiologically based pharmacokinetic modeling for the prediction of drug Clearance from neonates to adolescents. J Clin Pharmacol 59:189–197. https://doi.org/10.1002/jcph.1310

Article  CAS  PubMed  Google Scholar 

Holford N, Heo Y-A, Anderson B (2013) A Pharmacokinetic Standard for Babies and adults. J Pharm Sci 102:2941–2952. https://doi.org/10.1002/jps.23574

Article  CAS  PubMed  Google Scholar 

Anderson BJ, Holford NHG (2009) Mechanistic basis of using body size and maturation to Predict Clearance in humans. Drug Metab Pharmacokinet 24:25–36. https://doi.org/10.2133/dmpk.24.25

Article  CAS  PubMed  Google Scholar 

Heimbach T, Lin W, Hourcade-Potelleret F et al (2019) Physiologically based pharmacokinetic modeling to supplement Nilotinib Pharmacokinetics and confirm dose selection in Pediatric patients. J Pharm Sci 108:2191–2198. https://doi.org/10.1016/j.xphs.2019.01.028

Article  CAS  PubMed  Google Scholar 

Krekels EHJ, Calvier EAM, van der Graaf PH, Knibbe CAJ (2019) Children are not small adults, but can we treat them as such? CPT Pharmacometrics Syst Pharmacol 8:34–38. https://doi.org/10.1002/psp4.12366

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Q, Peters SA (2019) A retrospective evaluation of Allometry, Population Pharmacokinetics, and physiologically-based pharmacokinetics for Pediatric Dosing using clearance as a surrogate. CPT Pharmacometrics Syst Pharmacol 8:220–229. https://doi.org/10.1002/psp4.12385

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ke APBPK (2023) Jul modeling and allometric scaling in pediatric drug development: where do we draw the line? https://cersi.umd.edu/sites/cersi.umd.edu/files/Day 1 Slide Set %281%29-1-83.pdf. Accessed 30

Lankheet NAG, Desar IME, Mulder SF et al (2017) Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol 83:2195–2204. https://doi.org/10.1111/bcp.13327

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu H, Steeghs N, Kloth JSL et al (2015) Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol 79:809–819. https://doi.org/10.1111/bcp.12550

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu H, van Erp N, Bins S et al (2017) Development of a pharmacokinetic model to describe the Complex Pharmacokinetics of Pazopanib in Cancer patients. Clin Pharmacokinet 56:293–303. https://doi.org/10.1007/s40262-016-0443-y

Article  CAS  PubMed  Google Scholar 

Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of Imatinib. Clin Pharmacokinet 44:879–894. https://doi.org/10.2165/00003088-200544090-00001

Article  CAS  PubMed  Google Scholar 

Willmann S, Lippert J, Sevestre M et al (2003) PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model. BIOSILICO 1:121–124. https://doi.org/10.1016/S1478-5382(03)02342-4

Article  CAS  Google Scholar 

Kabir MZ, Tee W-V, Mohamad SB et al (2017) Comprehensive insight in